# A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Source: https://onco.cc/trials/nct07015242/  
OnCo record `nct07015242` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rituximab, Methotrexate, Procarbazine, Temozolomide, Lisocabtagene maraleucel and Fludarabine in non-Hodgkin lymphoma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.

## Summary

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma is a phase 2 interventional study registered as NCT07015242 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 65 participants planned, started 2025-11-06 and due to reach its primary completion in 2028-01-09. Interventions recorded: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel and Fludarabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07015242
- Phase: 2
- Setting: The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
- Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Enrolled: 65

## Sources

- ClinicalTrials.gov NCT07015242: https://clinicaltrials.gov/study/NCT07015242

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Fludarabine](https://onco.cc/drugs/fludarabine/), [Lisocabtagene maraleucel](https://onco.cc/drugs/lisocabtagene-maraleucel/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Procarbazine](https://onco.cc/drugs/procarbazine/), [Rituximab](https://onco.cc/drugs/rituximab/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct07015242.json